Abstract 19799: The Addition of Galectin-3 Significantly Improves Upon the Ability of Discharge BNP to Predict 60 Day Readmission for Acute Decompensated Heart Failure
Introduction: Acute decompensated heart failure (ADHF) is a major reason for repeated hospitalizations. Identifying those patients with HF at risk for readmission is critical so that preventative interventions can be implemented. Biomarkers such as BNP and galectin-3 (Gal-3) assessed at discharge may potentially be useful, though their role in predicting short-term readmission is not well defined in literature.
Methods: We enrolled and had follow up data for 91 participants admitted to our facility between 4/2013 and 1/2014 with a primary diagnosis of ADHF. Gal-3 and BNP were obtained within 48 hours prior to hospital discharge after management for ADHF. Gal-3 was assessed using a commercially available assay. We compared subjects who were and were not readmitted (re-ad).
Results: Discharge BNP was found to be a significant predictor of 30 and 60 day readmission [AUC 0.69 (p=0.046), AUC 0.7 (p=0.005) respectively]. The addition of Gal-3 to discharge BNP provided significantly improved prediction of 60 day re-admission. The net reclassification improvement (NRI) was 55.2% (p=0.037). 14% of re-admitted participants were correctly reclassified and 41% of non-readmitted patients were correctly reclassified using this approach. A statistically significant NRI was not found upon examination of 30 day readmission.
Conclusions: Measurement of both Gal-3 and BNP at hospital discharge provides significant prediction of hospital re-admission within 60 days. When combined, the prediction of re-admission is significantly improved. This data will be useful to help identify those at-risk of re-admission and aid in efficiently implementing appropriate interventions to reduce re-admission rates.
Author Disclosures: S. Sudharshan: None. E. Novak: None. M. Rosario: None. M.G. Scott: None. E.M. Geltman: None.
- © 2014 by American Heart Association, Inc.